Cortisone and cortisol break hydrogen-bonding rules to make a drug–prodrug solid solution by Verma, Vivek et al.
research papers




Received 17 August 2020
Accepted 3 October 2020
Edited by L. R. MacGillivray, University of Iowa,
USA
Keywords: solid solutions; mixed crystals;
multidrug formulations; steroids;
pharmaceutical solids; assisted spray drying;
hydrogen bonding; hydrocortisone; cortisone.
CCDC references: 2010415; 2010416;
2010417; 2010418; 2010419
Supporting information: this article has
supporting information at www.iucrj.org
Cortisone and cortisol break hydrogen-bonding
rules to make a drug–prodrug solid solution
Vivek Verma,a Simone Bordignon,b Michele R. Chierotti,b Monica Lestari,a Kieran
Lyons,a Luis Padrela,a Kevin M. Ryana and Matteo Lusia*
aDepartment of Chemistry and Bernal Institute, University of Limerick, Limerick, Ireland, and bDipartimento di Chimica,
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Multidrug products enable more effective therapies and simpler administration
regimens, provided that a stable formulation is prepared, with the desired
composition. In this view, solid solutions have the advantage of combining the
stability of a single crystalline phase with the potential of stoichiometry variation
of a mixture. Here a drug–prodrug solid solution of cortisone and cortisol
(hydrocortisone) is described. Despite the structural differences of the two
components, the new phase is obtained both from solution and by supercritical
CO2 assisted spray drying. In particular, to enter the solid solution,
hydrocortisone must violate Etter’s rules for hydrogen bonding. As a result,
its dissolution rate is almost doubled.
1. Introduction
Modern medical therapies rely on increasingly complex
pharmaceutical regimens that include multiple drugs with
synergistic or complementary effects. In the case of chronic
conditions, such therapies may be continued throughout the
patient’s life. Multidrug formulations could reduce drug
dosage and potential side effects whilst simplifying adminis-
tration regimens (Aljuffali et al., 2016; Okuda & Kidoaki,
2012; Das et al., 2010). Such products can often be prepared as
physical mixtures of the active pharmaceutical ingredients
(APIs) in the desired dose, although the resulting multiphase
system might be difficult to process and to store over time
(Raimi-Abraham et al., 2017). Alternatively, a stable crystal-
line phase can be obtained by combining multiple active
ingredients in a cocrystal (Kavanagh et al., 2019a; Bordignon et
al., 2017). Cocrystals possess the advantages of a single phase
but their fixed stoichiometry does not allow for the adjustment
of the APIs dose, which is necessarily dictated by therapeutic
considerations rather than crystallographic ones (Kavanagh et
al., 2019b). A third approach can be imagined that involves
crystalline molecular solid solutions (Lusi, 2018a), which
combine the simplicity of a single crystalline phase with the
stoichiometry variability of a physical mixture.
Solid solutions are commonly employed in inorganic
chemistry and metallurgy, whereas their molecular subgroup
remains largely understudied. Besides a few notable excep-
tions (Mishra et al., 2015; Braga et al., 2009; Delori et al., 2014),
the dominant perception around these phases is that they are
difficult to make (Lusi, 2018b). Indeed, empirical rules
originally formulated by Hume-Rothery (1926) and Kitaigor-
odsky (1984) prescribe that only atoms and molecules of the
same size, charge and shape can mutually substitute each other
in the solid state. Moreover, complete solubility is only
deemed possible for those compounds that produce isostruc-
tural (and/or isomorphous) crystals (Kitaigorodsky, 1984). In
particular, it was suggested that in order to form a mixed
crystal, molecules must have equivalent hydrogen-bond
donors and acceptors. From a crystal-engineering perspective,
such a requirement can be seen as a direct consequence of
Etter’s rule for hydrogen bonds: ‘All good proton donors and
acceptors are used in hydrogen bonding’ (Etter, 1990) – a rule
that is generally followed in the known crystal structures with
a few exceptions owing to steric hindrance (Wood & Galek,
2010). Ultimately, only a subset of molecules, often differing
by a methyl or a halogen substituent, would fulfil Hume-
Rothery and Kitaigorodsky prescriptions. Such conditions
represent a bottleneck to the development of pharmaceutical
solid solutions (Etter, 1990).
In contrast, recent work shows that appropriate design
strategies can enable mixed crystals despite the lack of
isostructurality (Schur et al., 2015) or large size difference
(Lestari & Lusi, 2019) of the parent components. Other works
show that the appropriate synthetic conditions could afford
long-lasting metastable products – as an example, solvent-
assisted grinding can afford solid solutions that are not
available by conventional techniques (Chierotti et al., 2010). In
fact, for non-stoichiometric systems, the complex equilibria
between liquid and solid phases often hinders the preparation
of a uniform product. In those cases, mechanochemical reac-
tions might afford better control over the product by avoiding
a liquid phase (Lusi, 2018b). Similarly, the kinetic control
possible through rapid expansion of supercritical solutions
(RESS) processes affords high miscibility in the solid solutions
of anthracene/phenanthrene (Liu & Nagahama, 1996), l-
leucine/l-isoleucine and l-leucine/l-valine (Raza et al., 2018).
With these premises we believe that the investigation of
novel pharmaceutical solid solutions and their potential scale
up by such methods is meritable of attention. In particular, we
wanted to test whether solid solutions could be formed for
molecules that have different hydrogen-bonding capabilities
and are not isostructural. To this end, our attention was
directed to two steroids: cortisone (C) and hydrocortisone
(HC).
Owing to their extensive use in medicine, many steroids are
synthesized and commercialized as slow-releasing formula-
tions that help in maintaining the ideal blood concentration
for prolonged periods of time (Paik et al., 2019; Krasselt &
Baerwald, 2016). Over five decades ago, steroids were among
the earliest APIs to be co-crystallized as solid solutions and
eutectic mixtures (Rudel, 1974; Castellano et al., 1980).
Interestingly, solid solutions are also reported for pairs of
steroids such as arenobufagin/gamabufotalin and cinobufagin/
cinobufotalin (Kálmán & Párkány, 1997), which are ‘essen-
tially isostructural’ despite their different hydrogen-bond
capabilities. In fact, for large and non-polar molecules such as
steroids, the role of dispersive forces may become predomi-
nant over hydrogen bonds (Thompson & Day, 2014).
C was the first steroid to be employed as a replacement in
adrenocortical deficiency states (Benedek, 2011; Hench et al.,
1949). Nowadays, it is largely substituted by its more soluble
metabolite: cortisol (HC), the most widely used steroidal anti-
inflammatory drug, listed by the World Health Organization as
an essential medicine (Garay et al., 2007). For this drug, the
topical market alone is estimated at 3 billion USD globally.
C and HC differ only in the substituent in the C11 position,
a carbonyl and a hydroxyl moiety, respectively (Fig. 1), and
their metabolism is closely related. In fact, C can be seen as a
prodrug (Becker, 2001) of HC, being converted to the latter by
the 11-hydroxysteroid dehydrogenase (Lakshmi & Monder,
1985; Edwards et al., 1988). From a pharmaceutical perspec-
tive, it can be imagined that a solid form that includes both
molecules could help maintain the desired plasma concen-
tration for a prolonged period reducing the number of doses
and simplifying their administration.
2. Results and discussion
2.1. Single-crystal analysis
Despite their similar biochemical functions, C and HC are
rather different from a supramolecular point of view. They
crystallize in different structures and show different poly-
morphism. C has only one known polymorph in the P212121
space group [CCDC (Groom et al., 2016) refcode DHPRTO;
Declercq et al., 1972], while three polymorphs of HC are
known: forms I (CCDC refcode ZZZPNG01) and III (CCDC
refcode ZZZPNG03) in the P212121 space group and form II
(CCDC refcode ZZZPNG02) in the monoclinic P21 space
group (Suitchmezian et al., 2008). No evident structural simi-
larity is recognisable in these structures (Kálmán & Párkány,
1997), phenomena that can be explained in terms of the
different hydrogen-bond capabilities of the substituents,
carbonyl and hydroxyl, on the C11.
Slow solvent evaporation of alcoholic solutions of C and HC
in 2:1, 1:1 and 1:2 ratios provided colourless crystals. Single-
crystal X-ray diffraction (XRD) revealed that the crystals are
all isomorphous to the C structure (CCDC refcode
DHPRTO). The C11–O11 bond lengths for the single crystals
isolated from the solutions measure 1.25, 1.29 and 1.31 Å,
respectively (Table 1). These values fall between those of pure
C (C = O = 1.21 Å) and those of pure HC (C–O = 1.43 Å) and
suggest the formation of a solid solution. The poor resolution
of standard XRD does not allow for the refinement of the
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Figure 1
Schematic representations of C (left) and HC (right), with C atom
numbering.
oxygen substituent as a split atom (carbonyl versus hydroxyl
group), nor for the reliable refinement of hydrogen-atoms
occupancy (Lusi & Barbour, 2011). Similarly, the single crys-
tals are too small for high-performance liquid chromatography
(HPLC) analysis. The occupancy refinement for the hydrogen
atoms on C11 and on the adjacent O11 was attempted for a
mere aesthetical end. The single crystals, isolated at the
beginning of the crystallization, appear enriched in HC. Inci-
dentally, when the C–O bond lengths are plotted against the
calculated occupancy, a second-order relation emerges (see
Fig. S1 in the Supporting information).
A qualitative understanding of the structure modifications
that occur with substitution can be proposed using Hirshfeld
surface analysis. Here the (virtual) replacement of a HC
molecule in the structure of C would result in a short H  H
contact (1.8 Å) between the hydroxyl group O11 and C7 in
the adjacent molecule (Fig. 2). This value is 20% shorter
than the expected contact distance based on the Bondi radius
(1.1 Å). At the same time, any rotation of the OH group is
sterically hindered by the presence of the adjacent methyl
carbons C18 and C19, which suggests that the substitution
would rapidly increase the enthalpy of the crystal. As a
response, when the amount of HC increases, the structure
progressively relaxes to accommodate the bulkier hydroxyl
substituent (Table 1). The structure adjustments have negli-
gible effects on the contact surface of C but the H  H contact
distance for HC increases to above 2 Å. A similar phenom-
enon was observed in the phenazine/acridine system,
confirming the importance of structure modulability for the
successful realization of solid solutions (Schur et al., 2015).
The correct identification and quantification of all the
energy contributions in such a disordered system is not
straightforward and it is beyond the scope of this work, though
an estimate of the energies can be performed in Crystal
Explorer (Turner et al., 2017) for the C and HC molecules in
the different structures. The results indicate that the overall
interaction energy for the HC molecule in the structure of
pure C is12 kJ mol1 higher than that of the C molecule (see
Table S1 in the Supporting information). The main difference
is caused by the higher repulsion occurring with another HC
molecule related by simple translation along the a axis
(identified as x, y and z in Table S1 and coloured in green in
Fig. 2). Although, part of the repulsion is compensated by a
greater dispersive contribution. As the substitution increases
and the structure adjusts, the repulsion contribution between
this pair of HC molecules is progressively reduced and,
eventually, the total interaction energy calculated for HC
becomes comparable with the one calculated for C. Notably,
the structural and compositional variations along the series
seem to have little effect on the other molecular interactions.
Invariantly, the largest contribution to the molecular packing
comes from the dispersive interaction with the molecule along
the b screw axis (identified as x, y + 1/2, z + 1/2 in Table S1
and coloured in violet in Fig. 2).
2.2. Bulk synthesis and properties
Based on previous experience, solvent assisted co-grinding
of the two molecules was attempted to make a bulk product
with homogenous 2:1, 1:1 and 1:2 ratio compositions. The
research papers
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Table 1
Crystallographic data for single crystals of C, HC and their solid solutions.
C C:HC ’ 2:1 C:HC ’ 1:2 C:HC ’ 1:3 HC form I
a (Å) 7.7819 (4) 7.7442 (6) 7.7308 (7) 7.76953 (9) 10.1439 (14)
b (Å) 10.0468 (5) 10.0968 (8) 10.1237 (9) 10.1258 (11) 12.4255 (16)
c (Å) 23.6401 (13) 23.6750 (19) 23.694 (2) 23.694 (3) 30.496 (5)
Volume (Å3) 1848.26 (17) 1851.2 (3) 1854.4 (3) 1854.4 (3) 3843.8 (10)
Space group P212121 P212121 P212121 P212121 P212121







Mr 360.43 361.18 361.71 361.92 359.42
Dx (g cm
3) 1.295 1.296 1.296 1.306 1.242
Z 4 4 4 4 8
R (reflections) 0.0504 (3395) 0.0747 (2479) 0.0715 (1824) 0.0715 (1824) 0.0969 (931)
Temperature (K) 296 296 296 296 296
C–O distance (Å) 1.208 1.255 1.288 1.311 1.457
Hirshfeld plot of cortisone
Hirshfeld plot of hydrocortisone
persistence of a diffraction peak at 17.5 shows that a phase
mixture was obtained (Fig. 3). Such qualitative conclusions are
confirmed by Rietveld refinement, according to which the
relative amount of each phase coincides with that of the
starting materials (Table S1). On the contrary, the same
technique indicates that a single microcrystalline phase is
obtained when CO2 is employed in a supercritical CO2 assisted
spray drying (SASD) process (Long et al., 2019, 2020; Padrela
et al., 2017) (Fig. 3). In this case, peak broadening indicates
smaller crystallites.
The spray-drying methods ensure that the overall stoi-
chiometry of the microcrystalline product coincides with that
of the liquid phase. Within the bulk, product uniformity is
confirmed by solid-state nuclear magnetic resonance
(SSNMR). 13C cross-polarization magic angle spinning
(CPMAS) spectra of the solid solutions are consistent with
those of pure C, but with apparent differences, especially in
the number of signals (Fig. 4). This agrees with the fact that
the structure of pure C is maintained in the solid solutions,
with HC as a guest molecule. The homogeneous nature of the
microcrystalline product was further confirmed by 1H T1
relaxation measurements acquired through 13C (not shown).
Indeed, the 1H T1 values are the same for each
13C signal,
indicating active spin diffusion processes, i.e. homogeneous
domains over a 100 nm scale. The CPMAS technique is
intrinsically non-quantitative, since the intensity of each
spectral resonance depends both on their TXH (the cross-
polarization rate) and their T1
H (the proton spin-lattice
relaxation in the rotating frame). However, the two CH groups
in C and HC are the same functional group (namely, the
olefinic CH group – C4), in the same chemical environment of
two almost identical and rigid molecules (or in any case with
very similar mobility) in the same unit cell. Therefore, it is
reasonable and safe to think that the two CH groups in the two
molecules have almost identical TXH and T1
H values and the
same cross-polarization rate. Thus, 13C spectra were used to
achieve reliable quantitative information (Anelli et al., 2019).
Specifically, in order to assess the relative amounts of C and
HC in the solid solutions, a deconvolution was performed on
the signals in the 120–130 p.p.m. range. By considering the
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Figure 2
Part of the packing features of HC in the structure of C. The green
molecule is generated by translation along a and the purple molecule is
generated by screw symmetry along b.
Figure 3
Powder XRD patterns measured for microcrystalline powder generated
by the SASD method (blue) and the mechanochemical product (red).
Figure 4
13C (100.63 MHz) CPMAS SSNMR spectra measured for the micro-
crystalline powder generated by the SASD method. The labels refer to
assignments of relevant peaks (see Fig. 1 for atom numbering).
resonances to be the result of slightly different contributions,
the deconvolution allowed the determination of the C:HC
ratio for the SASD products, in accordance with the nominal
ones (see Fig. S3).
Thermal analyses reveal that the solid solutions are
marginally lower melting than the pure compounds but remain
stable until 180 C (see Figs. S4 and S5). Finally, the solu-
bility of the new phase was assessed by measuring the intrinsic
solubility of C and HC in the solid solution and physical
mixture. Notably, in the solid solution the initial dissolution
rate of HC is twice that of pure HC (form I). On the contrary,
the dissolution rate of C is reduced in the solid solution (Fig.
5). This agrees with the common understanding that the
properties of solid solutions often vary regularly between
those of the pure components.
3. Conclusions
Drug/prodrug solid solutions of C and HC were prepared in
different stoichiometric ratios. The mixed-crystals results are
stable in spite of the different hydrogen-bond capabilities of
the two molecules and the different crystal structures of their
pure phases. We believe that the formation of the solid solu-
tion is possible because in large and non-polar molecules the
contribution of dispersive forces becomes predominant over
that of hydrogen bonds. Moreover, the host structure of C can
adjust to accommodate the hydroxyl group of the HC mole-
cule. Interestingly, a uniform polycrystalline phase could be
obtained by the SASD method, whereas the solvent
evaporation and mechanochemical techniques resulted in a
large compositional spread or a mixture of the pure compo-
nents, respectively.
From a pharmaceutical point of view, the solid solution
enables a faster dissolution rate of HC, which is up to twice
that measured for the pure compound. We speculate that the
higher solubility could increase the bioavailability of HC,
while the compresence of C could prolong the desired
concentration of the anti-inflammatory API in plasma. The
variable ratio of the solid solutions would then allow the
optimization of the correct dosage.
Ultimately, this work shows that mixed crystals represent a
viable alternative to physical mixtures and cocrystals to
formulate multidrug products. In particular, drug–prodrug
solid solutions would be particularly targetable because of the
structural similarity that is often observed between an active
molecule and its biological precursors.
4. Experimental
All reagents grade products were used as purchased without
further purification.
4.1. Solution synthesis
Single crystals of pure C and pure HC were recrystallized
from a solution of 0.2 mmol (72 mg) of the commercial
products in ethanol, by slow evaporation in ambient condi-
tions. The mixed crystals of C and HC in the 2:1, 1:1 and 1:2
ratios were obtained in the same conditions from ethanol
solutions containing: (a) 72.0 mg (0.2 mmol) of C and 36.3 mg
(0.1 mmol) of HC, (b) 54.1 mg (0.15 mmol) of C and 54.4 mg
(0.15 mmol) of HC, and (c) 36.1 mg (0.1 mmol) of C and
72.6 mg (0.2 mmol) of HC, respectively. Good-quality single
crystals were isolated from the liquid phase as soon as they
formed (within two or three days).
4.2. Mechanochemical synthesis
Solid-solution synthesis of C and HC in the 2:1, 1:1 and 1:2
ratios was attempted by manually grinding in an agate mortar:
(a) 72.0 mg (0.2 mmol) of C and 36.3 mg (0.1 mmol) of HC, (b)
54.1 mg (0.15 mmol) of C and 54.4 mg (0.15 mmol) of HC, and
(c) 36.1 mg (0.1 mmol) of C and 72.6 mg (0.2 mmol) of HC,
respectively. In each case, four to five (Pasteur pipette) drops
of ethanol were added to the mixture and machination
continued until a dry powder was obtained (5–10 min).
4.3. SASD synthesis
Solutions of either pure C or HC where prepared by
dissolving 150.0 mg of as-received powder in 20 ml of ethanol.
Solutions of the mixed steroids in the 2:1, 1:1 and 1:2 ratios
were prepared in 20 ml of ethanol by dissolving: (a) 100.0 mg
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Figure 5
Dissolution profiles of C and HC for the products generated by the SASD
method.
(0.28 mmol) of C and 50.0 mg (0.14 mmol) of HC, (b) 75.0 mg
(0.21 mmol) of C and 75.0 mg (0.21 mmol) of HC, and (c)
50.0 mg (0.14 mmol) of C and 100.0 mg (0.28 mmol) of HC,
respectively. Full dissolution was completed in an ultrasonic
bath (15 min). The solutions were then filtered through a
0.2 mm pore-size nylon filter (Whatman Inc., Florham Park,
New Jersey). An Agilent Technologies 1260 Infinity II pump
was used to pass the solutions at a flow rate of 0.2 ml min1
through a 0.1 cm3 high-pressure nozzle equilibrated at 70 C
with heating resistors. In the nozzle, the solutions were mixed
with a stream of CO2 compressed to 12 MPa using a SFE
Process DoseHPP 400-C pump. The supercritical mixture was
depressurized in a 1000 cm3 chamber in equilibrium with a
water jacket at 70 C, and the product collected on 0.2 mm
filter paper. The samples were harvested and stored in a
desiccator prior to characterization to prevent exposure to
humidity that results in solid-state transformation over time.
4.4. XRD analysis
Single-crystal XRD was performed in Bruker D8 Quest
single-crystal X-ray diffractometers with an Mo anode for C,
and a Cu anode for HC. Measurements were taken at an
ambient temperature. The intensities were integrated with
SHELX and SAINT in the Bruker APEX3 (Bruker, 2016)
suite of programs and a solution was found using direct
methods. Atomic positions and occupancies were refined
against all the F2obs values, and all non-hydrogen atoms were
treated anisotropically in SHELXL (Sheldrick, 2015) using
the X-SEED (Barbour, 2001) interface.
Powder XRD patterns were collected on a X’Pert Pro
instrument at 40 kVand 40 mA, with Cu K  = 1.54056 Å in a
– geometry. Data were measured from 4 and 40 2 with a
step size of 0.0167113 and a scan time of
19.685 seconds step1. Samples were placed in a zero-back-
ground disc. Rietveld refinement for mixture samples was
performed in HighScore Plus (Degen et al., 2014). Rietveld
refinement was performed for the mixture samples against the
pure C and HC crystal structures.
4.5. Hirshfeld surface analysis and energy calculation
Hirshfeld surface analysis was calculated with Crystal
Explorer 17 (Turner et al. 2017) for the molecules of C and HC
in the pure compounds and in the solid solutions. Since the
hydrogen-atom position cannot be reliably refined by XRD,
the hydrogen atoms were fixed according to the riding model
and their bond lengths normalized to the average neutron
data. In particular, for the HC molecule, the H-C11-O11-H
torsion angle was fixed to 45: the most common value
obtained as a result of the structure refinement. This precau-
tion allows a more direct comparison of the structural change
as a function of composition.
Interaction energies were calculated in Crystal Explorer 17
for a cluster containing the reference molecule and neighbour
molecules within a radius of 3.8 Å using the default setting and
the HF/3-21G basis set.
4.6. Solid-state NMR
Solid-state NMR spectra were acquired with a Bruker
Avance II 400 Ultra Shield instrument, operating at 400.23 and
100.63 MHz for 1H and 13C nuclei, respectively
The powder samples were packed into cylindrical zirconia
rotors with a 4 mm outer diameter and an 80 ml volume. A
certain amount of sample was collected from each batch and
used without further preparations to fill the rotor. 13C CPMAS
spectra were acquired at room temperature at a spinning
speed of 12 kHz, using a ramp cross-polarization pulse
sequence with a 90 1H pulse of 3.6 ms, a contact time of 3 ms,
optimized recycle delays ranging from 2.5–5.6 s and a number
of scans in the range 200–6500, depending on the sample. For
every spectrum, a two-pulse phase modulation decoupling
scheme was used, with a radiofrequency field of 69.4 kHz. The
13C chemical shift scale was calibrated through the methylenic
signal of external standard glycine (at 43.7 p.p.m.). As for the
13C T1-
1H analysis of the 1:1 solid solution, 13C spectra were
acquired for 320 scans with different relaxation delays,
included in the range 0.2–60 s and calculated by Bruker
TopSpin 2.1 software through an exponential algorithm.
In order to assess the relative amounts of C and HC in the
solid solutions, a deconvolution was performed on the signals
in the 120–130 p.p.m. range (Fig. 2). By considering the
resonances to be the result of slightly different contributions,
the deconvolution allowed us to determine that the C:HC ratio
for the SASD products is equal to 66.0:34.0, 49.7:50.3 and
35.2:64.8, in accordance with the nominal ones (2:1, 1:1 and
1:2, respectively).
4.7. Thermal analysis
Thermogravimetric analysis was performed on a TA
Instrument Q50 with aluminium sample pans. Samples were
heated to 400 C with a rate of 10 C min1 and nitrogen gas
flow rates of 60 ml min1. Differential scanning calorimetry
was performed on a TA Instrument Q2000 in sealed alumi-
nium pans with a heating rate of 10 C min1 and nitrogen gas
flow rates of 60 ml min1.
4.8. Solubility measurements
Intrinsic solubility measurements were performed in sink
conditions. 20 mg of each sample was dissolved in 1000 ml of
deionized water at 37 C at 150 rev min1. The sample was
collected at minutes 1, 3, 5, 10, 15, 30, 45 and 60 and filtered
through a 0.2 mm nylon filter. The HPLC system used was
Agilent Technologies 1260 Infinity with column Macherey-
Nagel EC100/4.6 Nucleodur 100-5C18ec. The mobile phase
used was methanol and water with a ratio of 1:1 at
1.0 ml min1 flow rate. 20 ml of the sample was injected into
the HPLC system. The system and the autosampler were at an
ambient temperature. Chromatograms were recorded at
248 nm with a run time of 12 min. The processing of the
chromatographic data was carried out in the software Chem-
station for liquid chromatography (Agilent Technologies).
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